Publications

Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients. by Freitas MCS, Pacheco-Silva A, Barbosa D, Silbert S, Sader HS, Sesso R and Camargo LFA published in BMC Inf. Dis. 2006; 6: 133

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. by Mariani PG, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2006; 58 (2): 481-483

Emergence of multidrug-resistant Streptococcus pneumoniae: Report from the SENTRY Antimicrobial Surveillance Program (1999-2003). by Johnson DM, Stilwell MG, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (1): 69-74

Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). by Kirby JT, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (1): 75-82

Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). by Rhomberg PR, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (1): 57-62

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant Gram-positive cocci. by Jones RN, Fritsche TR, Sader HS and Ross JE published in Antimicrob. Agents. Chemother. 2006; 50 (7): 2583-2586

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. by Sader HS, Fritsche TR and Jones RN published in Antimicrob. Agents Chemother. 2006; 50 (7): 2330-2336

Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. by Johnson DM, Fritsche TR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2006; 27 (6): 557-560

Antimicrobial susceptibility of Gram-positive bacteria isolated from European Medical Centres: Results of the Daptomycin Surveillance Programme (2002-2004). by Sader HS, Streit JM, Fritsche TR and Jones RN published in Clin. Microbiol. Infect. 2006; 12 (9): 844-852

Dissemination of IMP-1 metallo-β-lactamase-producing Acinetobacter species in a Brazilian teaching hospital. by Tognim MCB, Gales AC, Penteago A, Silbert S and Sader HS published in Infect. Control Hosp. Epidemiol. 2006; 27 (7): 742-747

Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa with doripenem plus an aminoglycoside. by Huynh HK, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 55 (3): 241-243

Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: Are we evaluating the orally administered cephalosporins correctly? by Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2006; 55 (4): 351-356

Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. by Gales AC, Sader HS, Andrade SS, Lutz L, Machado A and Barth AL published in Int. J. Antimicrob. Agents 2006; 27 (4): 300-302

Clonal occurrences of multidrug-resistant Gram-negative bacilli: Report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 54 (4): 249-257

International surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003). by Messer SA, Jones RN and Fritsche TR published in J. Clin. Microbiol. 2006; 44 (5): 1782-1787

Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin. by Fernandez-Cuenca F, Martinez-Martinez L, Amblar G, Biedenbach DJ, Jones RN and Pascual A published in Clin. Microbiol. Infect. 2006; 12 (2): 197-198

Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gram-negative bacilli: Report from the SENTRY Antimicrobial Surveillance Programme (2001-2004). by Gales AC, Jones RN and Sader HS published in Clin. Microbiol. Infect. 2006; 12 (4): 315-321

Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum β-lactam agents. by Sader HS, Fritsche TR and Jones RN published in J. Clin. Microbiol. 2006; 44 (3): 1101-1104

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: Report from the SENTRY Antimicrobial Surveillance Program. by Bhavnani SM, Ambrose PG, Craig WA, Dudley MN and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 54 (3): 231-236

Emergence and epidemiology for fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: Report from the SENTRY Antimicrobial Surveillance Program (2001-2004). by Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 53 (3): 157-164

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. by Goldstein BP, Jones RN, Fritsche TR and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2006; 54 (2): 83-87

Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes. by Pottumarthy S, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 54 (2): 127-134

Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). by Jones RN, Stilwell MG, Sader HS, Fritsche TR and Goldstein BP published in Diagn. Microbiol. Infect. Dis. 2006; 54 (2): 149-153

Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum β-lactamase (ESBL) in a hospital with high prevalence of this infection. by Marra AR, Pereira CA, Castelo A, do Carmo Filho JR, Cal RG, Sader HS and Wey SB published in Int. J. Infect. Dis. 2006; 10 (1): 56-60

Contemporary antimicrobial activity of triple antibiotic ointment: A multiphased study of recent clinical isolates in the United States and Australia. by Jones RN, Li Q., Kohut B, Biedenbach DJ, Bell J, Turnidge JD published in Diagn. Microbiol. Infect. Dis. 2006; 54 (1): 63-71

Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables. by Hammel JP, Bhavnani SM, Jones RN, Forrest A, Ambrose PG published in Antimicrob. Agents Chemother. 2006; 50 (1): 62-67

Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: Report from the Sentry Antimicrobial Surveillance Program (1997-2004). by Biedenbach DJ, Toleman M, Walsh TR, and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 54 (1): 13-21

Oxazolidinone susceptibility patterns in 2004: Report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations. by Jones, R.N., Ross, J.E., Fritsche, T.R., and Sader, H.S. published in J. Antimicrob. Chemother. 2006; 57 (2): 279-287

Carbapenem susceptibility discords among Acinetobacter isolates. by Jones RN, Sader HS, Fritsche TR and Rhomberg PR published in Clin, Infect. Dist. 2006; 42 (1): 158

Dissemination of bla_vim among Clonally Unrelated Clinical Strains Isolated in an USA Medical Center, Lead author: Sader HS, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Emergence of Imp and Vim Metallo-Beta-Lactamase Producing P. aeruginosa Strains in Mexico: Report from the Sentry Antimicrobial Surveillance Program, Lead author: Sader HS, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Evaluation of Daptomycin (DAP), Telavancin (TLV), Teicoplanin (TEI), and Vancomycin (VAN) Activity in the Presence of Albumin or Serum, Lead author: Tsuji, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

In Vitro Susceptibility Testing Guidelines for Ceftobiprole (BAL9141) Using CLSI Disk Diffusion and Broth Microdilution MIC Methods, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Accuracy for Antibacterial and Antifungal Susceptibility Tests: Report from the College of American Pathologists (CAP) Microbiology Proficiency Survey Program for 2004 – 2005, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Susceptibility Testing Accuracy of an Enterobacteriaceae Population Enriched for Ctx-M-Type ESBL-Producing Isolates (China): Intermethod Analysis for Nine Important Parenteral ß-Lactams, Lead author: Pottumarthy S, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Importance of Medium, Calcium Concentration, Time of Incubation, and Inoculum for Testing Polymyxin B (PB) against Acinetobacter spp. (ASP) and Pseudomonas aeruginosa (PSA), Lead author: Mendes RE, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Validation of Etest Colistin (CO) and Polymyxin B (PO) against the CLSI Reference Methods using 413 Strains with a Wide Susceptibility Range, Lead author: Bolmstrom A, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Wild-Type MIC Distributions for Campylobacter spp. Tested against Nine Antimicrobials using Recently Approved CLSI Broth Microdilution (BMD) Methods (2005), Lead author: Fritsche TR, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Faropenem Activity Tested against Neisseria gonorrhoeae Including Contemporary Antimicrobial Resistance Phenotypes, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Tigecycline (GAR-936) Activity against 850 Bloodstream Infection (BSI) Isolates of Viridans Group Streptococci, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Antimicrobial Spectrum and Potency of Cefepime Combined with Sulbactam when Tested with 4 Candidate Ratio or Fixed Concentration Formulations, Lead author: Sader HS, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Activity of a Novel Cationic Steroid Antimicrobial (CSA-13) Targeting Aerobic and Facultative Gram-negative Bacilli, Gram-positive Anaerobes and Select Agent Surrogate Strains, Lead author: Savage, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Activity of a Novel Cationic Steroid Antimicrobial (CSA-13) Against Staphylococcus aureus and Bacterial Species Associated with Infections in Cystic Fibrosis Patients, Lead author: Savage, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Antimicrobial Activity of BP-102, A Novel Carbacephem, Tested Against H. influenzae, M. catarrhalis and Various Gram-Positive Cocci, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Activity of VIC-105555 (VIC), a Novel Lincosamide, Tested Against Gram-Positive Bacteria and Anaerobes, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Comparative Antimicrobial Activity and Spectrum of Retapamulin (RE) Against Drug-Resistant Organisms, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Quality Control Guidelines for Testing Retapamulin by CLSI Broth Microdilution and Disk Diffusion Methods, Lead author: Jones RN, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Assessment of Pathogen Frequency and Resistance (R) Patterns Among Pediatric Patients (PP): Report from the SENTRY Antimicrobial Surveillance Program (2004) on Three Continents, Lead author: Fedler K, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Evaluation of Clinical Outcome among Patients with ESBL-Producing Enterobacteriaceae (ETB) Treated with Cephalosporin (CEPH) Monotherapy, Lead author: Craig WA, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC

Geographic Antimicrobial Resistance Variability among Bacterial Pathogens Causing Nosocomial Pneumonia in North America (NA): An Eight-Year Analysis from the SENTRY Antimicrobial Surveillance Program, 1997-2004, Lead author: Biedenbach DJ, presented at 45th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December 16 – 19, 2005, Washington, DC